The board refresh adds a high-profile retinal specialist aligned with the company's lead GA program, but is a routine governance change with no immediate financial catalyst. Monitor for pivotal Phase 3 data for vonaprument and any partnering or financing moves as the company approaches registration.
Price Chart
Executive Summary
Annexon announced the resignation of board member Muneer Satter (after 11+ years) and the immediate appointment of Dr. Mark S. Blumenkranz, a renowned retinal surgeon and biotech entrepreneur, to its board. Blumenkranz brings deep ophthalmic expertise as the company advances late-stage programs, particularly vonaprument in geographic atrophy. The filing contains no financial data; it is a routine board refresh with strategic alignment.
Key Facts
- Muneer Satter resigned from the board effective August 10, 2026, with no disagreement cited.
- Mark S. Blumenkranz, M.D., M.M.S., appointed to the board effective August 10, 2026, as a Class II director serving until the 2028 annual meeting.
- Blumenkranz co-founded or led Adverum Biotechnologies, Optimedica (acquired by Abbott), Oculeve (acquired by Allergan), and Kedalion Therapeutics (acquired by Novartis).
- Blumenkranz received an initial option grant of 175,000 shares and an automatic annual option grant of 65,000 shares under the 2020 Plan, plus a $40,000 annual retainer.
- The company highlighted Blumenkranz's expertise as it advances vonaprument in geographic atrophy and prepares for potential commercialization.
Financial Impact
No financial data or material impact disclosed; director compensation totals ~$40,000/year plus options.
Risk Factors
- No clinical or regulatory data in this filing; the stock remains driven by pipeline milestones.
- Satter's departure removes a long-tenured board member with deep investor ties, though it appears amicable.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342524 |
| Document: d130710dex991.htm | 0001193125-26-342524 |
| Document: 0001193125-26-342524-index-headers.html | 0001193125-26-342524 |
| Document: 0001193125-26-342524-index.html | 0001193125-26-342524 |
| Document: 0001193125-26-342524.txt | 0001193125-26-342524 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 10w ago | ANALYST-UPGRADE | $5.26 $5.18 | ▼ −1.52% | ▲ +0.44% | $3.70 (−29.66%) |
Aug 12, 2026 10w ago | 8-K | $5.33 $5.50 | ▲ +3.19% | ▲ +3.63% | $3.70 (−30.58%) |
Aug 12, 2026 10w ago | Press Release | $5.33 $5.50 | ▲ +3.19% | ▲ +3.63% | $3.70 (−30.58%) |
Aug 10, 2026 11w ago | 8-K | $5.34 $5.28 | ▼ −1.12% | ▼ −0.72% | $3.70 (−30.71%) |
Aug 7, 2026 11w ago | Institutional Cluster | $5.41 $5.29 | ▼ −2.22% | ▼ −2.62% | $3.70 (−31.61%) |
Aug 6, 2026 11w ago | Press Release | $5.60 $5.26 | ▼ −6.07% | ▼ −7.28% | $3.70 (−33.93%) |
Jul 21, 2026 13w ago | ANALYST-UPGRADE | $5.39 $5.13 | ▼ −4.82% | ▼ −3.60% | $3.70 (−31.35%) |
Jul 14, 2026 14w ago | 144 | $5.55 $5.57 | ▲ +0.36% | ▲ +1.66% | $3.70 (−33.33%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.70 $4.94 | ▲ +5.11% | ▲ +4.67% | $3.70 (−21.28%) |
May 12, 2026 23w ago | ANALYST-UPGRADE | $5.44 $4.96 | ▲ +8.82% | ▲ +8.90% | $3.70 (+31.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers